Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3‐year follow‐up

Abstract

Our study suggests that early initiation of enzyme replacement therapy may significantly slow or prevent the development of irreversible disease manifestations and therefore modify the natural history of MPS II.